Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

TRACER

99 years and younger
All genders
There is evidence that GALAD, a score that incorporates 3 blood based biomarkers and patient age and sex may be more effective than standard of care screening at detecting HCC early in patients with liver cirrhosis or chronic hepatitis B. Patients undergoing liver cancer screening will be enrolled, then randomized …
Learn More

IDEAL

99 years and younger
All genders
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Learn More

ACT18018

99 years and younger
All genders
This study will look at the efficacy, safety, and tolerability of itepekimab, in people with non-cystic fibrosis bronchiectasis. Patients will be asked to complete a CT, lab tests, safety labs, lung function tests, PEs, ECGs, and questionnaires.
Learn More

TRIOMPHE Study

99 years and younger
All genders
Prospective, nonrandomized, multicenter clinical investigation of the NEXUS Aortic Arch Stent Graft System (NEXUS) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Learn More

UPCC 16524: A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of Intratumorally Administered INT230-6 (SHAO, vinblastine, cisplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, Inoperable, or

99 years and younger
All genders
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless …
Learn More

UPCC 02522 A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (

99 years and younger
All genders
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Learn More

UPCC 18524: A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

99 years and younger
All genders
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. We would like to rely on CIRB as the IRB of record for this study.
Learn More

UPCC 36424 Phase 2, Open-Label, Multicenter, Dose-Optimization Study of the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Volasertib in Combination With Decitabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

99 years and younger
All genders
The purpose of this study is to test the safety and tolerability of volasertib combined with decitabine in participants with relapsed/refractory acute myeloid leukemia. We would like to rely on Advarra IRB as the IRB of record for this study.
Learn More

UPCC 35424 TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

99 years and younger
All genders
Please refer to Protocol Section 2.1 (Objectives). Please refer to Protocol Section 2.2.1 (Primary Endpoints). Please refer to Protocol Section 2.2.2 (Secondary Endpoints).
Learn More

AHAEmi

99 years and younger
All genders
The primary objective of the present study is to evaluate the efficacy (effectiveness) of prophylactic (preventative doses) of emicizumab (FDA approved, also called Hemlibra) administered on a regular scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA). The secondary objectives are to study the safety of emicizumab …
Learn More
831 - 840 of 930